Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
NCT00319748
Adnexal Diseases, Breast Cancer
Minneapolis, Minnesota, United States
View Trial DetailsNCT Number: NCT01691144
Follow-up of cancer patients accounts for a substantial part of outpatient activity, and alternative models of care are developing. In some countries, low-risk follow-up is already done in primary care, mainly in breast, and colorectal cancer. In this study the investigators will explore gynecological cancer patients about their expectations regarding their future follow-up plan. Further, the investigators will ask about the experience and satisfaction among patients who have already attended a follow-up programme for 2-3 years. In addition, the investigators will especially focus on the cooperation aspect between primary and secondary care. The investigators hypothesize that follow-up of selected gynecological cancer patients can be done by general practitioners.
Looking for future studies?
Notify Me19 year and older
Female
Observational
Sorlandet Hospital Kristiansand, Kristiansand, Norway
After gynaecological cancer patients have completed their treatment, they are followed up at a gynaecological outpatient clinic for a number of years. The aim of such follow-up is to detect recurrence, improve survival and reduce adverse effects of the treatment. The national guide for oncological gynaecology recommends follow-up by a specialist for five years at intervals depending on cancer type. Several review studies on follow-up of endometrial, cervical and ovarian cancer patients show large international variations in follow-up routines. There are only retrospective studies available, and they indicate that most recurrences are discovered within the first three years after completed treatment, and, in most cases, by the women themselves. More intensive surveillance does not appear to affect the time for discovery of recurrence.
A few randomised controlled studies and retrospective cohort studies have been published that focus on follow-up of colon cancer and breast cancer patients by general practitioners versus by hospital specialists. These studies have not shown any significant differences between the groups in terms of detection of recurrence, incidence of serious clinical events connected with recurrence or health-related quality of life.
The investigators therefore plan to perform a study in which both gynaecological cancer patients and their regular general practitioners are asked about their views on patient follow-up after completed treatment. The investigators especially wish to focus on the collaboration aspect.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: within the first 30 days after primary treatment
The patients will be asked to fill in a quesionnaire regarding their expectations on follow-up care
Time frame: 3 years after treatment
The patients will be asked to fill in a quesionnaire regarding their satisfaction on follow-up care after three years
University of Oslo
Other
Gynecological Cancer Survivors' Views on Follow-up After Cancer Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00319748
Adnexal Diseases, Breast Cancer
Minneapolis, Minnesota, United States
View Trial DetailsNCT00604994
Adnexal Diseases, Cervical Cancer
Camperdown, New South Wales, Australia
View Trial DetailsNCT07059884
Adnexal Diseases, Anal Cancer
Dublin, California, United States
View Trial DetailsNCT05086692
Acral Melanoma, Adenocarcinoma
San Diego, California, United States
View Trial Details